At the news
? NEUTRALIMPACT 4/10 COURT-RULING filed Aug 16, 2026 at 20:00 ET
A Markman claim construction ruling in a patent case brought by the University of Texas against Alnylam over its drug ONPATTRO. The court adopted constructions favorable to Alnylam on two key terms, defining 'liposome' narrowly as requiring an inner aqueous medium (excluding micelles) and ruling that the phospholipid component must contain no lysophosphatides, while rejecting Alnylam's proposed constructions on other terms. This is an interlocutory ruling that shifts the probability of eventual infringement liability but does not resolve the case, and the mixed outcome limits its immediate market impact.
- The court construed 'liposome' as 'a lipid vehicle having one or more lipid bilayers or aggregates surrounding an inner aqueous medium,' adopting Alnylam's proposed construction.
- The court ruled that 'the phospholipid is not a lysophosphatidylcholine or lysophosphatidylethanolamine' means 'the phospholipid component contains no lysophosphatidylcholine or lysophosphatidylethanolamine,' also adopting Alnylam's construction.
- The court rejected Alnylam's proposed constructions for 'a lipid component' and 'a phospholipid component,' instead adopting modified versions of the University's proposals.
- The court declined to construe 'a neutral charge' and 'encapsulate the siRNA such that greater than 90% of the liposomes encapsulate siRNA,' finding they have plain and ordinary meaning.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access